WHO ICTRP trial
A real world study of the adjuvant therapy of apatinib mesylate tablet for…
ChiCTR1800018175 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR1800018175 |
|---|---|
| Public title | A real world study of the adjuvant therapy of apatinib mesylate tablet for high-risk postoperative recurrence of hepatocellular carcinoma |
| Scientific title | A real world study of the adjuvant therapy of apatinib mesylate tablet for high-risk postoperative recurrence of hepatocellular carcinoma |
| Primary sponsor | Chinese People's Liberation Army (PLA) General Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Phase | Post-market |
| Countries | China |
| Conditions | Liver cancer |
| Interventions | Case series:Taking apatinib mesylate tablets orally once a day, initial dose 250mg, 28 days is one medication cycle. The treatment ends when the patient develop cancer recurrence/metastasis or death. |
| Registration date | Sep 4, 2018 |
| Target size | Case series:500 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: